SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia

Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D. R., Dittmar, K., Kolitz, J. E., et al. (1999) · Blood · doi:10.1182/blood.v94.6.1840 · Cited by 2,634

Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage

Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H., & Schlossman, S. F. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1588 · Cited by 1,629

High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR

Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,172

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C. A., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 983

Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells

Terstappen, L. W. M. M., Huang, S., Safford, M., Lansdorp, P., & Loken, M. R. (1991) · Blood · doi:10.1182/blood.v77.6.1218.1218 · Cited by 845

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease

Hamblin, T. J., Orchard, J. A., Ibbotson, R. E., Davis, Z. A., Thomas, P., Stevenson, F. K., & Oscier, D. G. (2002) · Blood · doi:10.1182/blood.v99.3.1023 · Cited by 618

Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma

Lin, P. Y., Owens, R., Tricot, G. J. K., & Wilson, C. S. (2004) · American Journal of Clinical Pathology · doi:10.1309/74r4tb90buwh27jx · Cited by 454

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

Ibrahim, S., Keating, M. J., Do, K.-A., O'Brien, S. M., Huh, Y. O., Jilani, I. B., Lerner, S. A., Kantarjian, H. M., & Albitar, M. X. (2001) · Blood · doi:10.1182/blood.v98.1.181 · Cited by 451

CD38 and CD157: A long journey from activation markers to multifunctional molecules

Quarona, V., Zaccarello, G., Chillemi, A., Brunetti, E., Singh, V. K., Ferrero, E., Funaro, A., Horenstein, A. L., & Malavasi, F. (2013) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21092 · Cited by 269

Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy

Chung, C. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1871 · Cited by 36

Novel Immunotherapies for Multiple Myeloma

D’Agostino, M., Boccadoro, M., & Smith, E. L. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0397-7 · Cited by 37

CD38 is methylated in prostate cancer and regulates extracellular NAD+

Mottahedeh, J., Haffner, M. C., Grogan, T., Hashimoto, T., Crowell, P. D., Beltran, H., Sboner, A., Bareja, R., Esopi, D., Isaacs, W. B., et al. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0186-3 · Cited by 41

Induction Therapy for Newly Diagnosed Multiple Myeloma

Paul, B. A., Lipe, B. C., Ocio, E. M., & Usmani, S. Z. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238527 · Cited by 36

CD38 as theranostic target in oncology

Bocuzzi, V., Bridoux, J., Pirotte, M., Withofs, N., Hustinx, R., D’Huyvetter, M., Caers, J., & Marcion, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05768-6 · Cited by 36

Facts and Hopes in Multiple Myeloma Immunotherapy

Sperling, A. S., & Anderson, K. C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3600 · Cited by 34

Targeting CD38 in Neoplasms and Non-Cancer Diseases

Szlasa, W., Czarny, J., Sauer, N. J., Rakoczy, K., Szymańska, N., Stecko, J., Kołodziej, M., Kaźmierczak, M., & Barg, E. (2022) · Cancers · doi:10.3390/cancers14174169 · Cited by 34

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond

Roccatello, D., Fenoglio, R., Sciascia, S., Naretto, C., Rossi, D., Ferro, M., Barreca, A., Malavasi, F., & Baldovino, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114129 · Cited by 34

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies

Wu, H., & Zhao, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68148 · Cited by 33

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance

Novellis, D. D., Fontana, R., Giudice, V., Serio, B., & Selleri, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010645 · Cited by 34

Monoclonal antibodies in myeloma.

Sondergeld, P., van de Donk, N. W. C. J., Richardson, P. G. G., & Plesner, T. (2015) · PubMed · Cited by 32

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis

Bringhen, S., Pour, L., Vorobyev, V. I., Vural, F., Warzocha, K., Benboubker, L., Koh, Y., Maisnar, V., Karlin, L., Pavic, M., et al. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106576 · Cited by 31

How I treat relapsed myeloma

Bladé, J., Rosiñol, L., & de Larrea, C. F. (2015) · Blood · doi:10.1182/blood-2014-10-551531 · Cited by 31

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Schjesvold, F. H., Richardson, P. G. G., Facon, T. T. F., Alegre, A. M., Spencer, A. G., Jurczyszyn, A. J., Sunami, K., Frenzel, L., Min, C., Guillonneau, S., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.253450 · Cited by 30

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

Fau, J., Cheikh, R. E., Brillac, C., Koiwai, K., Mace, N., Campana, F., Sémiond, D., & Nguyen, L. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12561 · Cited by 30

Critical Role of Astrocyte NAD + Glycohydrolase in Myelin Injury and Regeneration

Langley, M. R., Choi, C., Peclat, T., Guo, Y., Simon, W. L., Yoon, H., Kleppe, L. S., Lucchinetti, C. F., Chini, C. C. S., Chini, E. N., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2264-20.2021 · Cited by 31

Targeting CD38 in Antibody-Mediated Rejection

Mayer, K. A., Budde, K., Diebold, M., Halloran, P. F., & Böhmig, G. A. (2025) · Transplant International · doi:10.3389/ti.2025.14343 · Cited by 29

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

Zhou, L., Zhang, Y., Leng, Y., Dai, Y., Kmieciak, M., Kramer, L. B., Sharma, K., Wang, Y., Craun, W., & Grant, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0713-x · Cited by 29

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 30

CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers

Jiao, Y., Yi, M., Xu, L., Chu, Q., Yan, Y., Luo, S., & Wu, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1814253 · Cited by 29

IFN-γ and CD38 in Hyperprogressive Cancer Development

Angelicola, S., Ruzzi, F., Landuzzi, L., Scalambra, L., Gelsomino, F., Ardizzoni, A., Nanni, P., Lollini, P., & Palladini, A. (2021) · Cancers · doi:10.3390/cancers13020309 · Cited by 30

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

Hiemstra, I. H., Santegoets, K. C. M., Janmaat, M. L., de Goeij, B. E. C. G., ten Hagen, W., van Dooremalen, S., Boross, P., van den Brakel, J. H. N., Bosgra, S., Andringa, G., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104663 · Cited by 29

Emerging antibodies for the treatment of multiple myeloma

Zagouri, F., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1186644 · Cited by 29

Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma

Kennedy, B. E., Sadek, M., Elnenaei, M. O., Reiman, T., & Gujar, S. A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.11.005 · Cited by 28

Evolving roles of CD38 metabolism in solid tumour microenvironment

Gao, L., Du, X., Li, J., & Qin, F. X.-F. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02052-6 · Cited by 26

Monoclonal antibodies in the treatment of AL amyloidosis: co‐targetting the plasma cell clone and amyloid deposits

Popková, T., Hájek, R., & Jelı́nek, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.16436 · Cited by 28

Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

Kumar, S. K. (2017) · Hematology · doi:10.1182/asheducation-2017.1.518 · Cited by 27

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

Ocio, E. M., Perrot, A., Bories, P., Miguel, J. F. S., Blau, I. W., Karlin, L., Martínez‐López, J., Wang, S., Bringhen, S., Marcatti, M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01936-7 · Cited by 27

Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma

Lee, S. J., & Borrello, I. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_12 · Cited by 27

Novel Agents in Multiple Myeloma

Szalat, R. E., & Munshi, N. C. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000355 · Cited by 27

Monoclonal Antibodies in Multiple Myeloma Come of Age

Raje, N. S., & Longo, D. L. (2015) · New England Journal of Medicine · doi:10.1056/nejme1509419 · Cited by 27

Peptide-targeted nanoparticles for tumor therapy

Sidorenko, V., Tobi, A., Sugahara, K. N., & Teesalu, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114195 · Cited by 26

Novel targets for the treatment of relapsing multiple myeloma

Giuliani, N., Accardi, F., Marchica, V., Palma, B. D., Storti, P., Toscani, D., Vicario, E., & Malavasi, F. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1624158 · Cited by 28

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies

Schriewer, L., Schütze, K., Petry, K., Hambach, J., Fumey, W., Koenigsdorf, J., Baum, N., Menzel, S., Rissiek, B., Riecken, K., et al. (2020) · Theranostics · doi:10.7150/thno.38533 · Cited by 27

Immunotherapeutic and Targeted Approaches in Multiple Myeloma

Nadeem, O., Tai, Y., & Anderson, K. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240886 · Cited by 26

CD38 Monoclonal Antibody Therapies for Multiple Myeloma

Wong, S. W. K., & Comenzo, R. L. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.642 · Cited by 26

Molecular dynamics of targeting CD38 in multiple myeloma

Malavasi, F., Faini, A. C., Morandi, F., Castella, B., Incarnato, D., Oliviero, S., Horenstein, A. L., Massaia, M., van de Donk, N. W. C. J., & Richardson, P. G. G. (2021) · British Journal of Haematology · doi:10.1111/bjh.17329 · Cited by 26

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115674 · Cited by 23

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma

Romano, A., Storti, P., Marchica, V., Scandura, G., Notarfranchi, L., Craviotto, L., Raimondo, F. D., & Giuliani, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684561 · Cited by 24

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma

Kassem, S., Diallo, B., El-Murr, N., Carrié, N., Tang, A., Fournier, A., Bonnevaux, H., Nicolazzi, C., Cuisinier, M., Reguigne-Arnould, I., et al. (2022) · Blood · doi:10.1182/blood.2021012448 · Cited by 24

Targeting CD38 for acute leukemia

Zhong, X., & Ma, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1007783 · Cited by 24

Papain‐treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti‐CD38‐based therapies

Carreño‐Tarragona, G., Cedena, M., Montejano, L., Alonso, R., Mirás, F., Valeri, A., Rivero, A., Lahuerta, J. J., & Martínez‐López, J. (2018) · Transfusion Medicine · doi:10.1111/tme.12508 · Cited by 24

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

Ackley, J. C., Ochoa, M. A., Ghoshal, D., Roy, K., Lonial, S., & Boise, L. (2021) · Cancers · doi:10.3390/cancers13194787 · Cited by 25

Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review

Nishida, H. (2021) · Cancers · doi:10.3390/cancers13112712 · Cited by 23

Antigen Loss after Targeted Immunotherapy in Hematological Malignancies

Zhou, T., & Wang, H. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.04.005 · Cited by 23

Development of Novel Immunotherapies for Multiple Myeloma

Al-Hujaily, E. M., Oldham, R. A. A., Hari, P., & Medin, J. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091506 · Cited by 25

Updating targets for natural killer/T-cell lymphoma immunotherapy

Xue, W., & Zhang, M. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0400 · Cited by 23

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Ailawadhi, S., Špıčka, I., Spencer, A. G., Lu, J., Oriol, A., Ling, S., Schjesvold, F. H., Berkovits, A., Hus, M., Li, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00744 · Cited by 22

Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease

Ashjian, E. J., & Redic, K. A. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215572036 · Cited by 22

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study

Boissel, N., Chevallier, P., Doronin, V., Griškevičius, L., Maschan, A., McCloskey, J. K., Rambaldi, A., Rossi, G., Sokolov, A. N., Wartiovaara‐Kautto, U., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4478 · Cited by 22

Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia

Brivio, E., Bautista, F. J., & Zwaan, C. M. (2024) · Haematologica · doi:10.3324/haematol.2023.283815 · Cited by 22

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

Usmani, S. Z., Karanes, C., Bensinger, W., D’Souza, A., Raje, N. S., Tuchman, S. A., Sborov, D. W., Laubach, J. P., Bianchi, G., Kanagavel, D., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01262-w · Cited by 22

The Cancer-Immunity Cycle in Multiple Myeloma

Casey, M., & Nakamura, K. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s305432 · Cited by 24

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model

Zannetti, B. A., Faini, A. C., Massari, E., Geuna, M., Maffini, E., Poletti, G., Cerchione, C., Martinelli, G., Malavasi, F., & Lanza, F. (2020) · Cells · doi:10.3390/cells9122666 · Cited by 22

Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy

Chen, X., Gao, Q., Roshal, M., & Cherian, S. (2023) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22113 · Cited by 24

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma

Bannas, P., & Koch‐Nolte, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02559 · Cited by 21

The multi-faceted potential of CD38 antibody targeting in multiple myeloma

Shallis, R. M., Terry, C. M., & Lim, S. H. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1990-2 · Cited by 20

Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date

Richter, J. R., Sanchez, L. J., & Thibaud, S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.04.004 · Cited by 20

CD38-Directed Therapies for Management of Multiple Myeloma

Hashmi, H., Husnain, M., Khan, A. Y., & Usmani, S. Z. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s259122 · Cited by 20

Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study

Richardson, P. G. G., Harrison, S. J., Bringhen, S., Schjesvold, F. H., Yong, K., Campana, F., Le-Guennec, S., Macé, S., & Dimopoulos, M. A. (2021) · Future Oncology · doi:10.2217/fon-2021-0568 · Cited by 20

Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment

Xu, Q., Liu, X., Mohseni, G., Hao, X., Ren, Y., Xu, Y., Gao, H., Wang, Q., & Wang, Y. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02664-1 · Cited by 20

Evolving Role of Daratumumab: From Backbencher to Frontline Agent

Jain, A., & Ramasamy, K. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.010 · Cited by 20

Targeted Therapies for Multiple Myeloma

Leow, C. C.-Y., & Low, M. S. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050334 · Cited by 21

Therapeutics to harness the immune microenvironment in multiple myeloma

Ignatz-Hoover, J. J., & Driscoll, J. J. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.23 · Cited by 21

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

Sunami, K., Suzuki, K., Ri, M., Matsumoto, M., Shimazaki, C., Asaoku, H., Shibayama, H., Ishizawa, K., Takamatsu, H., Ikeda, T., et al. (2020) · Cancer Science · doi:10.1111/cas.14657 · Cited by 19

The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies

Swan, D., Routledge, D. J. M., & Harrison, S. J. (2021) · British Journal of Haematology · doi:10.1111/bjh.17805 · Cited by 19

Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins

Magarotto, V., Salvini, M., Bonello, F., Bringhen, S., & Palumbo, A. P. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1102245 · Cited by 18

Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy

Malavasi, F., & Faini, A. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0260 · Cited by 18

Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells

Baum, N., Fliegert, R., Bauche, A., Hambach, J., Menzel, S., Haag, F., Bannas, P., & Koch‐Nolte, F. (2020) · Cancers · doi:10.3390/cancers13010076 · Cited by 18

How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma

Hofmeister, C. C., & Lonial, S. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.5908 · Cited by 18

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis

Facon, T. T. F., Moreau, P., Martin, T. G., Špıčka, I., Oriol, A., Koh, Y., Lim, A. B. M., Mikala, G., Rosiñol, L., Yağcı, M., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3038 · Cited by 18

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

Royle, K., Coulson, A. B., Ramasamy, K., Cairns, D. A., Hockaday, A., Quezada, S. A., Drayson, M. T., Kaiser, M., Owen, R. G., Auner, H. W., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063037 · Cited by 17

Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia

Benkißer-Petersen, M., Buchner, M., Dörffel, A., Minden, M. D.-V., Claus, R., Kläsener, K., Leberecht, K., Burger, M., Dierks, C., Jumaa, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0169159 · Cited by 17

Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma

Elnair, R. A., & Holstein, S. A. (2021) · Drugs · doi:10.1007/s40265-021-01514-0 · Cited by 17

Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma

Sun, H., Martin, T. G., Marra, J. D., Kong, D., Keats, J., Macé, S., Chiron, M., Wolf, J. L., Venstrom, J. M., & Rajalingam, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002958 · Cited by 17

Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells

Gambles, M. T., Li, J., Wang, J., Sborov, D. W., Yang, J., & Kopec̆ek, J. (2021) · Molecules · doi:10.3390/molecules26154658 · Cited by 17

Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia

Wang, A., Song, Z., Zheng, G., Nicolazzi, C., Fromm, J. R., Shehu, E., Srinivasan, S. S., Chen, X., Zhu, C. Y., Blondel, M. C., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0058 · Cited by 19

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

Martin, T. G., Mikhael, J. R., Hájek, R., Kım, K., Suzuki, K., Hulin, C., Garg, M. K., Quach, H., Sia, H., George, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006713 · Cited by 17

Novel investigational drugs active as single agents in multiple myeloma

D’Agostino, M., Salvini, M., Palumbo, A. P., Larocca, A., & Gay, F. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1324571 · Cited by 16

Reprint of “Immunomodulatory effects of CD38-targeting antibodies”

van de Donk, N. W. C. J. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.02.002 · Cited by 16

Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia

Xia, M., Zhang, H., Lu, Z., Gao, Y., Liao, X., & Li, H. (2016) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000624 · Cited by 15

89Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas

Álvarez, N. H., Michel, A. L., Viray, T. D., Mayerhoefer, M. E., & Lewis, J. S. (2023) · ACS Omega · doi:10.1021/acsomega.3c00624 · Cited by 15

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

Cho, S., Lin, L., Xing, L., Yu, T., Wen, K., Anderson, K. C., & Tai, Y. (2017) · Antibodies · doi:10.3390/antib6040018 · Cited by 16

Monoclonal Antibodies in the Treatment of Multiple Myeloma

van de Donk, N. W. C. J., & Zweegman, S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.002 · Cited by 16

Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab

Ku, M., Chong, G., & Hawkes, E. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.08.001 · Cited by 14

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study

Lesokhin, A. M., LeBlanc, R., Dimopoulos, M. A., Capra, M., Carlo‐Stella, C., Karlin, L., Castilloux, J., Forsberg, P. A., Parmar, G., Tosikyan, A., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5753 · Cited by 14

How validated receptor occupancy flow cytometry assays can impact decisions and support drug development

Moulard, M., & Ozoux, M. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21320 · Cited by 15

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma

Kriegsmann, K., Dittrich, T., Neuber, B., Awwad, M. H. S., Hegenbart, U., Goldschmidt, H., Hillengaß, J., Hose, D., Seckinger, A., Müller‐Tidow, C., et al. (2018) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21636 · Cited by 14

Epigenome-Driven Strategies for Personalized Cancer Immunotherapy

Rocha, G. I. Y., Gomes, J. E. M., Leite, M. L., da Cunha, N. B., & Costa, F. F. (2023) · Cancer Management and Research · doi:10.2147/cmar.s272031 · Cited by 15

Immunotherapy Strategies in Multiple Myeloma

Bae, J. E., Munshi, N. C., & Anderson, K. C. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.07.002 · Cited by 13

CD38 targeted treatment for multiple myeloma

Jelı́nek, T., Mihályová, J., & Hájek, R. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.131 · Cited by 12

Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

Martin, T. G., Shah, N. D., Richter, J. R., Vesole, D. H., Wong, S. W. K., Huang, C., Madduri, D., Jagannath, S., Siegel, D. S. D., Biran, N., et al. (2021) · Cancer · doi:10.1002/cncr.33448 · Cited by 14

Antibody mimicry, receptors and clinical applications

Horenstein, A. L., Chillemi, A., Quarona, V., Zito, A., Mariani, V., Faini, A. C., Morandi, F., Schiavoni, I., Ausiello, C. M., & Malavasi, F. (2016) · Human Antibodies · doi:10.3233/hab-160305 · Cited by 14

Practical Considerations for Antibodies in Myeloma

Laubach, J. P., van de Donk, N. W. C. J., Davies, F. E., & Mikhael, J. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_205443 · Cited by 13

Therapeutic antibodies for multiple myeloma

Ishida, T. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy133 · Cited by 13

CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents

Becherini, P., Soncini, D., Ravera, S., Gelli, E., Martinuzzi, C., Giorgetti, G., Cagnetta, A., Guolo, F., Ivaldi, F., Miglino, M., et al. (2023) · Antioxidants · doi:10.3390/antiox12020494 · Cited by 12

A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma

Braunstein, M. J., Weltz, J., & Davies, F. E. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1909469 · Cited by 13

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma

Mustafa, N. B., Nee, A. H. F., Chooi, J.-Y., Toh, S. H. M., Chung, T., Selvarajan, V., Fan, S., Ng, S., Poon, M., Chan, E. H. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002123 · Cited by 12

Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma

Quach, H., Parmar, G., Mateos, M., Ailawadhi, S., & Leleu, X. P. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.02.004 · Cited by 11

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study

Decaux, O., Fontan, J., Perrot, A., Karlin, L., Touzeau, C., Schulmann, S., Manier, S., Belhadj, K., Trebouet, A., Zunic, P., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14225 · Cited by 11

SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies

Park, P. U., Blanc, V., Deckert, J., Lejeune, P., Bartle, L. M., Skaletskaya, A., Mayo, M., Zhang, C., Wetzel, M.-C., Tavares, D., et al. (2008) · Blood · doi:10.1182/blood.v112.11.2756.2756 · Cited by 6

Abstract 5469: SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma.

Hann, B. C., Cai, T., Wang, D., Hom, Y. K., Aftab, B. T., Martin, T. G., & Wolf, J. L. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-5469 · Cited by 2

Abstract 4735: SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies.

Wetzel, M.-C., Nicolazzi, C., Vallée, F., Deckert, J., Dumontet, C., Pleșa, A., Kannt, A., Mikol, V., Chiron, M., Vincent, L., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4735 · Cited by 3

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Peipp, M., de Weers, M., Beyer, T. D., Repp, R., Parren, P. W. H. I., Valerius, T., & van de Winkel, J. G. J. (2005) · Blood · doi:10.1182/blood.v106.11.3377.3377 · Cited by 1

Abstract #2048: SAR650984, a humanized anti-CD38 antibody, shows potent in vitro activity by multiple mechanisms against various hematologic tumor cell lines.

Deckert, J., Yi, Y. W., Chicklas, S., Mayo, M., Chittenden, T. W., & Park, P. U. (2009) · Cancer Research